Schumacher Ross C, Chiu Chia-Ying, Lubarda Jovana, Aboulsaoud Pakinam, Bomberger Jennifer, Wells J Michael
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, and.
Lung Health Center, University of Alabama at Birmingham, Birmingham, Alabama.
ATS Sch. 2023 Aug 17;4(4):490-501. doi: 10.34197/ats-scholar.2023-0028OC. eCollection 2023 Dec.
Alpha-1 antitrypsin deficiency (AATD) is the most common genetic risk factor for early-onset emphysema. However, AATD continues to be underrecognized and underdiagnosed. Provider awareness about AATD, concerns with testing costs, and limited understanding about therapeutic options contribute to its underdiagnosis. We hypothesized that provider education would improve awareness of AATD and improve screening.
To evaluate the impact of a targeted provider education module on AATD screening.
We developed a web-based education module to address barriers to screening for AATD, deployed the education module using the Medscape Education platform, assessed perceived healthcare provider confidence in AATD screening, and conducted a prospective pre and postintervention study of AATD testing practices at a high-volume academic outpatient subspecialty pulmonary clinic.
A total of 11,385 healthcare providers, including eight pulmonologists at our institution, completed the web-based education module. Confidence in identifying patients at high risk for AATD improved after completing the module ("not confident" in AATD screening was 7.7% postintervention compared with 19.4% preintervention). The rate of screening patients at high risk for AATD improved more than twofold (AATD screening rate 9.7% preintervention vs. 20.4% postintervention; = 0.004). Among patients screened for AATD in our cohort, 27.2% had a genotype/phenotype or low alpha-1 antitrypsin concentration consistent with AATD.
Targeted healthcare provider education can improve the confidence in testing for AATD. Improvements in provider confidence corresponded to improvements in AATD screening in a subspecialty pulmonary clinic. More than one-fourth of screening tests suggested AATD, underpinning the value of testing in high-risk individuals.
α-1抗胰蛋白酶缺乏症(AATD)是早发性肺气肿最常见的遗传风险因素。然而,AATD仍未得到充分认识和诊断。医疗服务提供者对AATD的认知、对检测成本的担忧以及对治疗选择的了解有限,导致其诊断不足。我们假设对医疗服务提供者进行教育会提高对AATD的认识并改善筛查。
评估针对医疗服务提供者的教育模块对AATD筛查的影响。
我们开发了一个基于网络的教育模块,以解决AATD筛查的障碍,通过Medscape教育平台部署该教育模块,评估医疗服务提供者对AATD筛查的信心,并在一家大型学术门诊亚专科肺科诊所对AATD检测实践进行前瞻性干预前后研究。
共有11385名医疗服务提供者,包括我们机构的8名肺科医生,完成了基于网络的教育模块。完成该模块后,识别AATD高危患者的信心有所提高(干预后AATD筛查中“无信心”的比例为7.7%,而干预前为19.4%)。AATD高危患者的筛查率提高了两倍多(干预前AATD筛查率为9.7%,干预后为20.4%;P = 0.004)。在我们队列中接受AATD筛查的患者中,27.2%的基因型/表型或α-1抗胰蛋白酶浓度低与AATD一致。
针对医疗服务提供者的教育可以提高对AATD检测的信心。医疗服务提供者信心的提高与亚专科肺科诊所AATD筛查的改善相对应。超过四分之一的筛查试验提示AATD,这支持了对高危个体进行检测的价值。